Business
Ornate Crown
Getty Images
Exec-odus

Nearly 2,000 CEOs left their jobs in the US last year, a record high

Nike, Boeing, Starbucks, and Peloton all have one thing in common: a new, expensive chief executive tasked with turning their company’s fortunes around.

Claire Yubin Oh

Whether theyre resigning, retiring, or being shown the door, more US CEOs said goodbye to their companies last year, with 1,991 CEOs exiting their firms in 2024, per a new report. That’s the highest year-to-date figure since the outplacement firm Challenger, Gray & Christmas started tracking turnovers in 2002 and a ~60% increase from only two years ago.

CEO departures
Sherwood News

No industry has been immune from this exec-odus, and interestingly, the trend is equally pronounced for publicly traded companies: 327 CEOs departed their firms last year, compared to 199 in 2022 and 300 in 2023. This includes big names like Boeing, Starbucks, and Nike.

Top down

This mass corporate switcheroo comes at an optimistic time for much of America Inc., backed by massive stock-market gains of the last two years and record profitability. Some leaders have come under pressure for a lackluster stock price in a year when markets soared — none more so than Intel’s Pat Gelsinger, who resigned after its board lost confidence in his turnaround plans, after Intel missed much of the AI boom.

But it might not just be short-term stock envy that’s driving CEOs away; there may also be a pandemic hangover at play. Indeed, departures have been consistent except for a small dip during the Covid years, presumably because it didn’t seem prudent to change leadership during such a tumultuous time.

Last year’s churn could also reflect a growing risk appetite for “leaders who can navigate increasing complexity” across corporate America, said consulting firm Russell Reynolds via Yahoo Finance. Or, it may reflect another simple fact: CEOs have been getting older, with the average age of an S&P 1500 CEO rising from ~54 to ~59 in the last 15 years, per Business Insider. Maybe they’ve decided they’ve got enough in the bank and want to retire, or maybe they were replaced by an AI chatbot, which one China-based company claimed to do back in 2023.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.